Security key
18978H409
- Security type / class
- Equity / Stock
- Total 13F shares
- 40,594
- Total 13F value
- $55,208
- Share change
- +40,594
- SEC-reported price per share
- $1.36
- Number of holders
- 7
- Value change
- +$55,208
- Number of buys
- 7
Report period
Q1 2025
Institutions
7
Top holders
7
CNSP full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
CNS Pharmaceuticals, Inc. SEC filings
CNS Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 18978H409
Recent filing periods:
Ownership snapshot
Top reported holders of CNSP - CNS Pharmaceuticals, Inc. - Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Waldemar Priebe
Disclosed value leader
Waldemar Priebe
Comparable rows
0/15
Latest evidence
31 Dec 2024
3/4/5
13F
Highest disclosed value: $198,486
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Waldemar Priebe has the largest disclosed position value at $198.5K.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Waldemar Priebe's linked filing trail.
Disclosed position value
Top 5
Waldemar Priebe
$198.5K
Cortice Biosciences, Inc.
$172K
Carl Anthony Evans
$54.2K
JANE STREET GROUP, LLC
$50.5K
GEODE CAPITAL MANAGEMENT, LLC
$46.6K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Waldemar Priebe |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$198,486
156,807 shares
|
— | 06 Dec 2022 |
| Cortice Biosciences, Inc. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$172,010
573,368 shares
|
— | 30 Jul 2024 |
| Carl Anthony Evans |
3/4/5
Director
|
—
mixed-class rows
|
$54,165
501,001 shares
mixed-class rows
|
— | 08 Apr 2024 |
| JANE STREET GROUP, LLC |
13F
Company
|
—
denominator unverified
|
$50,537
419,737 shares
|
— | 31 Dec 2024 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
—
denominator unverified
|
$46,601
387,064 shares
|
— | 31 Dec 2024 |
| CITADEL ADVISORS LLC |
13F
Company
|
—
denominator unverified
|
$38,754
321,874 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
7
Shares
40,594
Rows available
7
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2026 Across Filers
Q1 2026 holders
1
Q1 2025 holders
7
Holder diff
6
| Investor | Q1 2026 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend